Intuitive Surgical’s innovative da Vinci 5 has established a prominent place in the realm of complex inpatient procedures due to its advanced features. However, the company’s SP platform is steadily gaining recognition as an effective solution for Ambulatory Surgical Centers (ASCs). As outpatient care continues to disseminate rapidly throughout the United States, Intuitive Surgical’s dual-platform strategy could be instrumental in acquiring expansion across diverse hospital and ASC environments.
Remarkably, in the second quarter of 2025, there was a surge of 88% in SP procedures year-over-year, revealing a growth in its utilization by 30%. Countries like Korea and Japan appear to be at the forefront of this adoption trend, which speaks volumes about the platform’s capacity to sustain high-efficiency, high-throughput programs.
SP’s structured, streamlined architecture seamlessly fits into the operational needs of ASCs where a compact footprint, quick turnover, and cost-efficiency are of utmost importance. A commendable initiative on the part of Intuitive Surgical is the introduction of SP-enabling tools such as staplers and new colorectal indications. These align perfectly with the kind of surgeries increasingly being performed in outpatient settings.
The financial rationale backing these moves is pretty clear. While hospitals are migrating to da Vinci 5, Intuitive Surgical is strategically positioning the SP as a compatible platform rather than a competitive one alongside Xi and da Vinci 5, which continue to hold fort in inpatient surgical suites. Additionally, as treatments shift further towards lower-cost outpatient settings, the company’s ability to adapt its portfolio will be a game-changer.
Other companies contributing to the growth of ASCs include STERIS STE and Conmed’s CNMD. STERIS is leveraging its infection prevention and perioperative portfolio and positioning itself as a key partner. Similarly, through the Buffalo Filter line of products, AirSeal, and BioBrace implants, CNMD is aligning itself with ASC economic needs.
Despite losing 15.5% in shares year to date, Intuitive Surgical’s valuation still trades at a forward price-to-earnings ratio of 49.26, which is above the industry average but below its five-year median. It carries a Zacks Rank #4, implying the need for cautious investment.